MaxCyte, Inc. (MXCT)
NASDAQ · Healthcare
MaxCyte, Inc. annual/quarterly shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- MaxCyte, Inc. shareholder equity for the quarter ending December 31, 2025 were 171.5M, a 16.85% decrease year-over-year.
- MaxCyte, Inc. shareholder equity for 2025 were 171.5M, a 16.85% decrease from 2024.
- MaxCyte, Inc. shareholder equity for 2024 were 206.3M, a 11.16% decrease from 2023.
- MaxCyte, Inc. shareholder equity for 2023 were 232.2M, a 8.58% decrease from 2022.
- MaxCyte, Inc. shareholder equity for 2022 were 254.0M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| MaxCyte, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $171 |
| 2024 | $206 |
| 2023 | $232 |
| 2022 | $254 |
| 2021 | $263 |
| 2020 | $33 |
| MaxCyte, Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $171 |
| 2024-12-31 | $206 |
| 2023-12-31 | $232 |
| 2022-12-31 | $254 |
| 2021-12-31 | $263 |
| 2020-12-31 | $33 |
MaxCyte, Inc. Shareholder Equity — FAQ
MaxCyte, Inc. (MXCT) shareholder equity over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MXCT's shareholder equity history?
The chart and table above show MaxCyte, Inc.'s shareholder equity by year and by quarter, including the growth rate.